Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.25317 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of chimeric antigen receptor T cells targeting cancer-expressing podocalyxin.
Regen Ther
March 2025
Department of Cancer Immunotherapy and Immunology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of CD19-positive B-cell malignancies. However, the field is rapidly evolving to target other antigens, such as podocalyxin (PODXL), a transmembrane protein implicated in tumor progression and poor prognosis in various cancers. This study explores the potential of PODXL-targeted CAR-T cells, utilizing a cancer-specific monoclonal antibody (CasMab) technique to enhance the specificity and safety of CAR-T cell therapy.
View Article and Find Full Text PDFCD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
Lupus Sci Med
January 2025
Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands.
CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, this therapy brings a new approach in resetting immune dysregulation and potentially providing long-term remission for patients with a refractory disease. Recent reports have highlighted its effectiveness in conditions such as SLE, systemic sclerosis and myositis.
View Article and Find Full Text PDF[Blinatumomab-based combination treatment for CD19-positive acute leukemia of an ambiguous lineage].
Zhonghua Xue Ye Xue Za Zhi
November 2024
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Key Laboratory of Thrombosis and Hemostasis Under Ministry of Health, Suzhou 215006, China.
Acute leukemia of ambiguous lineage (ALAL) is a rare type of acute leukemia and is extremely difficult to treat. Here, we present six patients with CD19-positive ALAL who were successfully treated with blinatumomab-based combination treatment in the front-line setting. Five were diagnosed with B-cell/myeloid mixed phenotype acute leukemia (MPAL) and one with B-cell/T cell MPAL.
View Article and Find Full Text PDF[The mechanisms and salvage treatment strategies underlying positive relapse following CD19 CAR-T cell therapy in B-acute lymphoblastic leukemia].
Zhonghua Xue Ye Xue Za Zhi
October 2024
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Approximately 50% of patients suffering from relapsed/refractory B-acute lymphoblastic leukemia (R/R B-ALL), experience relapse within one year, with around 60% of these relapses being antigen-positive, despite the transformative impact of chimeric antigen receptor (CAR) T cell therapy. The mechanisms underlying relapse are primarily associated with tumor heterogeneity, CAR-T cell dysfunction, subopimal in vivo expansion and persistence, and an inhibitory immune microenvironment. This review aims to investigate salvage strategies designed to enhance outcomes for patients undergoing relapse or disease progression following the CAR-T cell therapy.
View Article and Find Full Text PDFOutcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation.
Haematologica
October 2024
Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesu Children's Hospital; Catholic University of the Sacred Heart, Rome.
Article Synopsis
- Blinatumomab shows strong effectiveness in treating relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in children and young adults, often leading to hematopoietic stem cell transplantation (HSCT).
- In a study with 78 patients, the 2-year disease-free survival (DFS) was 72.2% and overall survival (OS) was 89.2%, with low non-relapse mortality at 2.6%.
- Patients who were in first complete remission had better DFS compared to those in later remissions, and those receiving both inotuzumab and blinatumomab had lower relapse rates post-HSCT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!